SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes

Lignende værker

• Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice
  af: Klimontov, Vadim V, et al.
  Udgivet: (2020)
• Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
  af: Takahashi, Hiroyuki, et al.
  Udgivet: (2019)
• Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
  af: Jojima, Teruo, et al.
  Udgivet: (2016)
• Linagliptin alleviates fatty liver disease in diabetic db/db mice
  af: Michurina, Svetlana V, et al.
  Udgivet: (2016)
• Multiplex Bead Array Assay of a Panel of Circulating Cytokines and Growth Factors in Patients with Albuminuric and Non-Albuminuric Diabetic Kidney Disease
  af: Klimontov, Vadim V., et al.
  Udgivet: (2020)